Collaborative permeation of drug and excipients in transdermal formulations. In vitro scrutiny for ethanol: limonene combinations

dc.contributor.authorBoix Montañés, Antonio de Pádua
dc.contributor.authorCelma-Lezcano, Carles
dc.contributor.authorObach Vidal, Rosendo
dc.contributor.authorPeraire i Guitart, Concepció
dc.date.accessioned2024-10-25T10:21:39Z
dc.date.available2024-10-25T10:21:39Z
dc.date.issued2022-11-13
dc.date.updated2024-10-25T10:21:39Z
dc.description.abstractEnhancement of skin permeation of drugs is affected by the simultaneous co-permeation of excipients that hinder the predictivity of in vitro tests. The collaborative effects of two permeation enhancers (ethanol and d-limonene) of a lipophilic drug (alprazolam) have been simultaneously assessed in human skin under different in vitro conditions: integrated setups of diffusion cell experiments with selective concentration gradients of permeants (asymmetric) or without (symmetric) have been combined with coadministration dosages (all-in-one) at different concentrations or short-time skin pretreatment to scrutiny this mutual performance. Findings: Drug permeation is increased under moderated supersaturation but reaches a stationary level above 33 % of its solubility. Ethanol in absence of a concentration gradient increases ca.5 times basal drug permeation. Limonene until 20 % permeates human skin proportionally to its donor concentration but its effect does not depend on ethanol in symmetric conditions and is based on skin imbibition rather than on a carry-on effect. Simultaneous permeation of ethanol and limonene reaches a stationary state after 1.5 h, enough time to achieve maximal enhancement of alprazolam permeation. Additive enhancement is based on ethanol solubilisation maximized by skin saturation of terpene. Complementary analyses of skin disruption published in the literature are in line with these assessments and consolidate them.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec732795
dc.identifier.issn0939-6411
dc.identifier.urihttps://hdl.handle.net/2445/216042
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ejpb.2022.11.004
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2022, vol. 181, p. 239-248
dc.relation.urihttps://doi.org/10.1016/j.ejpb.2022.11.004
dc.rightscc-by-nc-nd (c) Antonio de Pádua Boix Montañés, et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMedicació transdèrmica
dc.subject.classificationBenzodiazepines
dc.subject.otherTransdermal medication
dc.subject.otherBenzodiazepines
dc.titleCollaborative permeation of drug and excipients in transdermal formulations. In vitro scrutiny for ethanol: limonene combinations
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
259779.pdf
Mida:
1.34 MB
Format:
Adobe Portable Document Format